Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Aneta Myšková, David Sýkora, Jaroslav Kuneš & Lenka Maletínská. (2023) Lipidization as a tool toward peptide therapeutics. Drug Delivery 30:1.
Read now
Read now
Waleed Albaker, Mona Al Sheikh, Aishah Albakr, Dania Alkhafaji, Eman Al Besher & Mohammed Al-Hariri. (2021) The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients. International Journal of General Medicine 14, pages 8643-8650.
Read now
Read now
Xiang Ren, Lingmin Sun, Limin Wei, Junli Liu, Jiaxu Zhu, Quanquan Yu, Hui Kong & Li Kong. (2020) Liraglutide Up-regulation Thioredoxin Attenuated Müller Cells Apoptosis in High Glucose by Regulating Oxidative Stress and Endoplasmic Reticulum Stress. Current Eye Research 45:10, pages 1283-1291.
Read now
Read now
Chen-Hsiu Lin, Li Shao, Yu-Mei Zhang, Yu-Ju Tu, Yuzhen Zhang, Brian Tomlinson, Paul Chan & Zhongmin Liu. (2020) An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert Opinion on Pharmacotherapy 21:3, pages 275-285.
Read now
Read now
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan & Zhong-Min Liu. (2016) Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opinion on Investigational Drugs 25:10, pages 1167-1179.
Read now
Read now
Articles from other publishers (46)
Signe Foghsgaard, Louise Vedtofte, Emilie S. Andersen, Emilie Bahne, Camilla Andreasen, Anne L. Sørensen, Julie L. Forman, Elisabeth R. Mathiesen, Jens A. Svare, Tine D. Clausen, Peter Damm, Jens J. Holst, Filip K. Knop & Tina Vilsbøll. (2023) Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial. Diabetes, Obesity and Metabolism 26:1, pages 201-214.
Crossref
Crossref
Tingli Guo, Wenhui Yan, Xin Cui, Na Liu, Xiaotong Wei, Yuzhuo Sun, KeXin Fan, Jieyun Liu, Yuanyuan Zhu, Zhuanzhuan Wang, Yilei Zhang & Lina Chen. (2023) Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis. Molecular Medicine 29:1.
Crossref
Crossref
Doaa A. Zaky, Rabab H. Sayed & Yasmin S. Mohamed. (2023) Liraglutide limits the immunogenic cell death-mediated ROS propagation and PI3K/AKT inactivation after doxorubicin-induced gonadotoxicity in rats: Involvement of the canonical Hedgehog trajectory. International Immunopharmacology 119, pages 110212.
Crossref
Crossref
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang & Jincheng Wang. (2023) Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition. Acta Pharmaceutica Sinica B 13:6, pages 2383-2402.
Crossref
Crossref
Youn-Goo Kang, Taeyoung Lee, Jaeyoung Ro, Sanghun Oh, Jin-Hwan Kwak & Ah-Ram Kim. (2023) Combination of Lactobacillus plantarum HAC03 and Garcinia cambogia Has a Significant Anti-Obesity Effect in Diet-Induced Obesity Mice. Nutrients 15:8, pages 1859.
Crossref
Crossref
Agnieszka Sienicka, Krzysztof Kubasik & Agata Pisula. (2023) The Glucagon-Like Peptide-1 Analogues therapy in the non-diabetic patients. Prospects in Pharmaceutical Sciences 21:1, pages 9-14.
Crossref
Crossref
Dilek Yazıcı, Hale Yapıcı Eser, Sinem Kıyıcı, Seda Sancak, Havva Sezer, Melin Uygur & Volkan Yumuk. (2023) Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. Obesity Facts 16:2, pages 149-163.
Crossref
Crossref
Fatemeh Mirzaei, Iraj Khodadadi, Nesrine Majdoub, Seyyed Alireza Vafaei, Heidar Tayebinia & Ebrahim Abbasi. (2022) Role of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Diabetic Patients with or without COVID-19. The Open Medicinal Chemistry Journal 16:1.
Crossref
Crossref
Hae-Jin Ko, Jin-Wook Kim & Soo Lim. (2022) Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting. Journal of Obesity & Metabolic Syndrome 31:3, pages 254-262.
Crossref
Crossref
Ruinan Wu, Zhanghan Wu, Liyun Xing, Xi Liu, Lei Wu, Zhou Zhou, Lian Li & Yuan Huang. (2022) Mimicking natural cholesterol assimilation to elevate the oral delivery of liraglutide for type II diabetes therapy. Asian Journal of Pharmaceutical Sciences 17:5, pages 653-665.
Crossref
Crossref
Xueyang Zhang, Yongbo Wang, Simengge Yang, Junwei Zong, Xuejiao Wang & Ran Bai. (2022) Beneficial effects of liraglutide on peripheral blood vessels. Vojnosanitetski pregled Military Medical and Pharmaceutical Journal of Serbia 79:2, pages 168-176.
Crossref
Crossref
Anas Hashem, Amani Khalouf & Andres Acosta. (2021) Management of Obesity and Nonalcoholic Fatty Liver Disease: A Literature Review. Seminars in Liver Disease 41:04, pages 435-447.
Crossref
Crossref
Marite Punapart, Kadri Seppa, Toomas Jagomäe, Mailis Liiv, Riin Reimets, Silvia Kirillov, Allen Kaasik, Lieve Moons, Lies De Groef, Anton Terasmaa, Eero Vasar & Mario Plaas. (2021) The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome. Genes 12:11, pages 1717.
Crossref
Crossref
Mariana Tilinca, Robert Tiuca, Cristina Niculas, Andreea Varga & Ioan Tilea. (2021) Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review). Experimental and Therapeutic Medicine 22:4.
Crossref
Crossref
Madeleine M. Fletcher, Peter Keov, Tin T. Truong, Grace Mennen, Caroline A. Hick, Peishen Zhao, Sebastian G.B. Furness, Thomas Kruse, Trine R. Clausen, Denise Wootten & Patrick M. Sexton. (2021) AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. Journal of Pharmacology and Experimental Therapeutics 377:3, pages 417-440.
Crossref
Crossref
Donald J. AbrahamMichael Wagner, Andreas Evers, Martin Bossart & Anish Konkar. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
69
.
Tingxu Yan, Tingting Nian, Fuyuan Li, Bosai He, Ying Jia, Kaishun Bi & Zhenzhong Wang. (2020)
Retracted
: Salidroside from
Rhodiola wallichiana
var.
cholaensis
reverses insulin resistance and stimulates the GLP‐1 secretion by alleviating ROS‐mediated activation of MAPKs signaling pathway and mitigating apoptosis
. Journal of Food Biochemistry 44:11.
Crossref
Crossref
Xueyang Zhang, Ran Bai, Yong Jia, Junwei Zong, Yongbo Wang & Yanan Dong. (2020) The effect of liraglutide on nonalcoholic fatty liver disease in type 2 diabetes mellitus. International Journal of Diabetes in Developing Countries 40:4, pages 491-499.
Crossref
Crossref
Manoel Galvao Neto, Rena C. Moon, Luiz Gustavo de Quadros, Eduardo Grecco, Admar Concon Filho, Thiago Ferreira de Souza, Luis Augusto Mattar, Jose Americo Gomides de Sousa, Barham K. Abu Dayyeh, Helmut Morais, Felipe Matz, Muhammad A. Jawad & Andre F. Teixeira. (2019) Safety and short-term effectiveness of endoscopic sleeve gastroplasty using overstitch: preliminary report from a multicenter study. Surgical Endoscopy 34:10, pages 4388-4394.
Crossref
Crossref
Mario Schubert, Sinah Hansen, Julian Leefmann & Kaomei Guan. (2020) Repurposing Antidiabetic Drugs for Cardiovascular Disease. Frontiers in Physiology 11.
Crossref
Crossref
Adrian Villalba, Silvia Rodriguez-Fernandez, David Perna-Barrull, Rosa-Maria Ampudia, Laia Gomez-Muñoz, Irma Pujol-Autonell, Eva Aguilera, Mireia Coma, Mary Cano-Sarabia, Federico Vázquez, Joan Verdaguer & Marta Vives-Pi. (2020) Repurposed Analog of GLP-1 Ameliorates Hyperglycemia in Type 1 Diabetic Mice Through Pancreatic Cell Reprogramming. Frontiers in Endocrinology 11.
Crossref
Crossref
Yanbo Di, Jing He, Ping Ma, Na Shen, Chunhong Niu, Xuan Liu, Xiaoming Du, Fengshi Tian, Huanming Li & Yong Liu. (2020) Liraglutide promotes the angiogenic ability of human umbilical vein endothelial cells through the JAK2/STAT3 signaling pathway. Biochemical and Biophysical Research Communications 523:3, pages 666-671.
Crossref
Crossref
You Han Bae & Kinam Park. (2020) Advanced drug delivery 2020 and beyond: Perspectives on the future. Advanced Drug Delivery Reviews 158, pages 4-16.
Crossref
Crossref
Giulia Cantini, Martina Trabucco, Ilaria Dicembrini, Edoardo Mannucci & Michaela Luconi. 2020. Hormonal Signaling in Biology and Medicine. Hormonal Signaling in Biology and Medicine
361
381
.
Liga Saulite, Kaspars Jekabsons, Maris Klavins, Ruta Muceniece & Una Riekstina. (2019) Effects of malvidin, cyanidin and delphinidin on human adipose mesenchymal stem cell differentiation into adipocytes, chondrocytes and osteocytes. Phytomedicine 53, pages 86-95.
Crossref
Crossref
C. K. Svensson, J. R. Larsen, L. Vedtofte, M. S. L. Jakobsen, H. R. Jespersen, M. I. Jakobsen, K. Koyuncu, O. Schjerning, J. Nielsen, C. T. Ekstrøm, C. U. Correll, T. Vilsbøll & A. Fink-Jensen. (2019) One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatrica Scandinavica 139:1, pages 26-36.
Crossref
Crossref
Chun-Mei Duan, Teng-Fei Wan, Yue Wang & Qing-Wu Yang. (2019) Cardiovascular outcomes of liraglutide in patients with type 2 diabetes. Medicine 98:46, pages e17860.
Crossref
Crossref
Liu GaoShi-Lun LiYu-Kun Li. (2018) Liraglutide Promotes the Osteogenic Differentiation in MC3T3-E1 Cells via Regulating the Expression of Smad2/3 Through PI3K/Akt and Wnt/β-Catenin Pathways. DNA and Cell Biology 37:12, pages 1031-1043.
Crossref
Crossref
Megan E Capozzi, Richard D DiMarchi, Matthias H Tschöp, Brian Finan & Jonathan E Campbell. (2018) Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. Endocrine Reviews 39:5, pages 719-738.
Crossref
Crossref
Finbarr P. M. O’Harte, Vadivel Parthsarathy, Christopher Hogg & Peter R. Flatt. (2018) Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice. PLOS ONE 13:8, pages e0202350.
Crossref
Crossref
Thomas A. Lutz. (2018) Considering our methods: Methodological issues with rodent models of appetite and obesity research. Physiology & Behavior 192, pages 182-187.
Crossref
Crossref
Elizabeth G. Mietlicki‐Baase, Claudia G. Liberini, Jayme L. Workinger, Ron L. Bonaccorso, Tito Borner, David J. Reiner, Kieran Koch‐Laskowski, Lauren E. McGrath, Rinzin Lhamo, Lauren M. Stein, Bart C. De Jonghe, George G. Holz, Christian L. Roth, Robert P. Doyle & Matthew R. Hayes. (2018) A vitamin B12 conjugate of exendin‐4 improves glucose tolerance without associated nausea or hypophagia in rodents. Diabetes, Obesity and Metabolism 20:5, pages 1223-1234.
Crossref
Crossref
L López-Ferreras, J E Richard, E E Noble, K Eerola, R H Anderberg, K Olandersson, L Taing, S E Kanoski, M R Hayes & K P Skibicka. (2017) Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight. Molecular Psychiatry 23:5, pages 1157-1168.
Crossref
Crossref
Darren M. Riddy, Philippe Delerive, Roger J. Summers, Patrick M. Sexton & Christopher J. Langmead. (2017) G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus. Pharmacological Reviews 70:1, pages 39-67.
Crossref
Crossref
Fiona M. Gribble, Frank Reimann & Geoffrey P. Roberts. 2018. Physiology of the Gastrointestinal Tract. Physiology of the Gastrointestinal Tract
31
70
.
Marcio C. Mancini & Maria Edna de Melo. (2017) The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetology & Metabolic Syndrome 9:1.
Crossref
Crossref
L. Engelbrechtsen, J. Lundgren, N. J. Wewer Albrechtsen, Y. Mahendran, E. W. Iepsen, P. Finocchietto, A. E. Jonsson, S. Madsbad, J. J. Holst, H. Vestergaard, T. Hansen & S. S. Torekov. (2017) Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obesity Science & Practice 3:4, pages 425-433.
Crossref
Crossref
Jennifer Pichette, Nancy Fynn-Sackey & Jeffrey Gagnon. (2017) Hydrogen sulfide and sulfate prebiotic stimulates the secretion of GLP-1 and improves glycaemia in male mice. Endocrinology.
Crossref
Crossref
K Kaineder, T Birngruber, G Rauter, B Obermüller, J Eichler, J Münzker, W Al-Zoughbi, S I Mautner, S S Torekov, B Hartmann, P Kotzbeck & T R Pieber. (2017) Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system. International Journal of Obesity 41:8, pages 1263-1270.
Crossref
Crossref
Rozita H. Anderberg, Jennifer E. Richard, Kim Eerola, Lorena López-Ferreras, Elin Banke, Caroline Hansson, Hans Nissbrandt, Filip Berqquist, Fiona M. GribbleFrank ReimannIngrid Wernstedt Asterholm, Christophe M. Lamy & Karolina P. Skibicka. (2017) Glucagon-Like Peptide 1 and Its Analogs Act in the Dorsal Raphe and Modulate Central Serotonin to Reduce Appetite and Body Weight. Diabetes 66:4, pages 1062-1073.
Crossref
Crossref
Katherine T. Tonks, Christopher P. White, Jacqueline R. Center, Dorit Samocha-Bonet & Jerry R. Greenfield. (2017) Bone Turnover Is Suppressed in Insulin Resistance, Independent of Adiposity. The Journal of Clinical Endocrinology & Metabolism 102:4, pages 1112-1121.
Crossref
Crossref
Renata Kowalczyk, Paul W. R. Harris, Geoffrey M. Williams, Sung-Hyun Yang & Margaret A. Brimble. 2017. Peptides and Peptide-based Biomaterials and their Biomedical Applications. Peptides and Peptide-based Biomaterials and their Biomedical Applications
185
227
.
Line Engelbrechtsen, Eva Pers Winning Iepsen, Ehm A. Andersson, Yuvaraj Mahendran, Julie Lundgren, Anna Elisabet Jonsson, Sten Madsbad, Jens Juul Holst, Henrik Vestergaard, Torben Hansen & Signe Sørensen Torekov. (2016) Weight loss and weight maintenance obtained with or without GLP-1 analogue treatment decrease branched chain amino acid levels. Metabolomics 12:12.
Crossref
Crossref
Shin J. Lee, Katharina Diener, Sharon Kaufman, Jean-Philippe Krieger, Klaus G. Pettersen, Nino Jejelava, Myrtha Arnold, Alan G. Watts & Wolfgang Langhans. (2016) Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4. Molecular Metabolism 5:7, pages 552-565.
Crossref
Crossref
Patricia L Brubaker & Manuel Gil‐Lozano. (2016) Glucagon‐like peptide‐1: The missing link in the metabolic clock?. Journal of Diabetes Investigation 7:S1, pages 70-75.
Crossref
Crossref
Simone Renner, Andreas Blutke, Elisabeth Streckel, Rüdiger Wanke & Eckhard Wolf. (2016) Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. The Journal of Pathology 238:2, pages 345-358.
Crossref
Crossref